Abstract
The serine/threonine kinase mechanistic target of rapamycin (mTOR) is an important sensor of the cellular energy condition which, at the same time, represents a kind of master switch between anabolic and catabolic cellular processes. Tuberous sclerosis complex (TSC) is a genetic disease which is considered to be a prototype of a dysregulated mTOR signaling pathway. The dysregulated mTOR pathway in TSC leads to characteristic structural and physiologic abnormalities in multiple organs. In this review we focus on the pharmacological properties of mTOR inhibitors and clinical investigations of mTOR inhibitors for two important neurological TSC manifestations: subependymal giant cell astrocytomas (SEGAs) and epilepsy. Moreover, we present a safety profile of those agents and their current role in clinical practice.
Keywords: mTOR inhibitors, TSC, SEGA, epilepsy, safety.
Current Medicinal Chemistry
Title:Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC
Volume: 23 Issue: 37
Author(s): Jasna Jancic, Vesna Duric, Nikola Ivancevic, Blazo Nikolic, John N. van den Anker and Janko Samardzic
Affiliation:
Keywords: mTOR inhibitors, TSC, SEGA, epilepsy, safety.
Abstract: The serine/threonine kinase mechanistic target of rapamycin (mTOR) is an important sensor of the cellular energy condition which, at the same time, represents a kind of master switch between anabolic and catabolic cellular processes. Tuberous sclerosis complex (TSC) is a genetic disease which is considered to be a prototype of a dysregulated mTOR signaling pathway. The dysregulated mTOR pathway in TSC leads to characteristic structural and physiologic abnormalities in multiple organs. In this review we focus on the pharmacological properties of mTOR inhibitors and clinical investigations of mTOR inhibitors for two important neurological TSC manifestations: subependymal giant cell astrocytomas (SEGAs) and epilepsy. Moreover, we present a safety profile of those agents and their current role in clinical practice.
Export Options
About this article
Cite this article as:
Jancic Jasna, Duric Vesna, Ivancevic Nikola, Nikolic Blazo, van den Anker N. John and Samardzic Janko, Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC, Current Medicinal Chemistry 2016; 23 (37) . https://dx.doi.org/10.2174/0929867323666161013091144
DOI https://dx.doi.org/10.2174/0929867323666161013091144 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Angiotensin Mediated Oxidative Stress and Neuroprotective Potential of Antioxidants and AT1 Receptor Blockers
Mini-Reviews in Medicinal Chemistry Study of Some Piperine Analogues on Drugs Efflux by Targeting P-glycoprotein, an in silico Approach
Letters in Drug Design & Discovery Mitochondrial Biogenesis: A Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerative Diseases
Current Pharmaceutical Design Insight into the Mechanism of the Four-Plate Test-Retest Procedure Using Etifoxine as Compared with Gabapentin
Current Psychopharmacology Dietary Interventions in Children with Autism Spectrum Disorders - An Updated Review of the Research Evidence
Current Clinical Pharmacology Recent Advances in the Synthesis of New Antimycobacterial Agents Based on the 1H-1,2,3-Triazoles
Current Topics in Medicinal Chemistry The Paradox of Caffeine-Zolpidem Interaction: A Network Analysis
Current Drug Targets Glial Cells – The Key Elements of Alzheimer´s Disease
Current Alzheimer Research Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition
Current Medicinal Chemistry Subject Index
Adolescent Psychiatry Therapeutic Potential of Erythropoietin in Retinal and Optic Nerve Diseases
CNS & Neurological Disorders - Drug Targets The Medical Implications of Gastrointestinal Vagal Afferent Pathways in Nausea and Vomiting
Current Pharmaceutical Design Ultrasonic Assisted Synthesis, Biological Evaluation, and Molecular Docking of Chalcone-based 1,5-benzodiazepine as Potential Anticonvulsant Agents
Current Enzyme Inhibition Role of Physical Exercise as Complementary Treatment for Epilepsy and other Brain Disorders
Current Pharmaceutical Design Current Issues on Epileptic Women
Current Pharmaceutical Design CSF as a Surrogate for Assessing CNS Exposure: An Industrial Perspective
Current Drug Metabolism Self-Regulatory Control and Habit Learning in the Development of Eating Disorders
Current Psychiatry Reviews Therapeutic Potential, Synthesis, Patent Evaluation and SAR Studies of Thieno[3,2-d]pyrimidine Derivatives: Recent Updates
Current Drug Targets Targeted Anti-leukemic Therapy as Disease-stabilizing Treatment for Acute Myeloid Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will it be Possible to Combine these Strategies with Retransplantation or Donor Lymphocyte Infusions?
Current Cancer Drug Targets